The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
Author Information
Author(s): Argyriou Pinelopi, Economopoulou Panagiota, Papageorgiou Sotirios
Primary Institution: Department of Pathology, “Evangelismos” General Hospital of Athens, Athens, Greece
Hypothesis
The study aims to summarize the existing knowledge about mTOR inhibitors and their use in the treatment of B-cell lymphomas.
Conclusion
mTOR inhibitors, particularly temsirolimus, show promise in treating relapsed or refractory mantle cell lymphoma and other B-cell lymphomas.
Supporting Evidence
- Temsirolimus has shown significant antitumor activity in relapsed or refractory mantle cell lymphoma.
- Everolimus and ridaforolimus have demonstrated promising antitumor activity against mantle cell lymphoma.
- Clinical trials indicate that mTOR inhibitors can improve response rates in patients with B-cell lymphomas.
Takeaway
Scientists are studying new medicines that can help treat certain types of blood cancers by blocking a pathway that helps cancer cells grow.
Methodology
The paper reviews clinical trials and studies involving mTOR inhibitors in various B-cell lymphomas.
Limitations
The study primarily focuses on specific types of B-cell lymphomas and may not generalize to all lymphoma types.
Participant Demographics
Patients with relapsed or refractory mantle cell lymphoma, median age 70 years.
Statistical Information
P-Value
0.0019
Statistical Significance
p=0.0019
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website